The global pulmonary arterial hypertension drugs market to grow at a CAGR of 3.2% during the period 2017-2021.
The report, Global Pulmonary Arterial Hypertension Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.
The latest trend gaining momentum in the market is increased focus on combination therapies. The PAH treatment is shifting toward the use of combination therapies that employ two or more drugs. A combination therapy with separate agents or a fixed dose of combination pill offers the maximum potential to lower blood pressure. The treatment is also aimed at targeting various disease mechanisms that may result in better outcome.
According to the report, one of the major drivers for this market is new disease-modifying therapies. Many new agents in the market are expected to show promising results in terms of efficacy as they target the receptors involved in the progression of PAH. For instance, OPSUMIT launched in 2013 in the US is an ERA, which mediates vasoconstriction, hypertrophy, and inflammation. The drug prevents the binding of endothelin (ET-1) to both endothelin receptors, ET-A and ET-B, resulting in decreased hypertension.
Other prominent vendors
DEKA Research & Development
Dong- A ST
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: An overview of PAH
PART 06: Pipeline analysis
PART 07: Market landscape
PART 08: Market segmentation by route of administration (RoA)
PART 09: Market segmentation by mechanism of action (MoA)